NorthStar Earth & Space Enterprises, Inc. (formerly Viking Acquisition Corp. I) filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $213,504 for the three-month period and total assets of $237,677,451.
Erasca, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting a net loss of $51.3 million for the third quarter and disclosing two underwritten common stock offerings completed …
Brightline Interactive, Inc./NV filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $1,436,789 and zero revenue from continuing operations.
Universal Logistics Holdings, Inc. filed its Form 10-Q for the quarterly period ended October 3, 2026, with the SEC on November 12, 2026, reporting a return to profitability in the third quarter compared to a significant net loss in the same period a year …
Fractyl Health, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, disclosing a strategic reprioritization adopted on October 21, 2026 that included a workforce reduction.
United States Antimony Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $9,526,056 for the three months ended September 30, 2026.
Jerash Holdings (US), Inc. filed its Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, reporting second-quarter and first-half financial results for fiscal year 2027.
Elite Pharmaceuticals, Inc. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, reporting condensed consolidated financial results for the three and six months ended on that date.
EyePoint, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting a net loss of $95.6 million for the third quarter and $274.9 million for the nine months ended September 30, 2026.
Relmada Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, disclosing a net loss of $13,862,188 for the third quarter and total assets of $205,296,615 as of that date.